The $100 Genome Is Here. The Hard Part Isn’t the Test.
Sequencing a genome now costs under $100. Banner Health's Dr. Alan Weiss asks the harder question: should you know something you cannot act on?
Sequencing a human genome cost $95 million in 2001. It is now under $100. We solved the hard technical problem, and in doing so created a harder human one: should you know something you can do nothing about?
That is the question Dr. Alan Weiss, SVP of Clinical Advancement at Banner Health, returns to Signal & Symptoms to explore, with host Dr. Junaid Kalia and co-hosts Dr. Isha Mannering, DR GPT™ Harvey Castro, and Edward Marx.
What this episode unpacks
- The worried well. A perfectly healthy colleague learned she carries risk for an untreatable rare cancer, and traded her peace of mind for a lifetime of watching every symptom.
- Where testing clearly wins. Pharmacogenomics (a fast codeine metabolizer changes the prescription) and newborn screening for treatable conditions are the clean cases.
- The capacity trap. Like the Apple Watch flooding cardiology with AFib alerts, a screening tool is only as useful as the system’s ability to act on it.
- The honest confession. Offered widespread testing, a genomics-literate physician said no.
The takeaway is not anti-testing. It is that testing at scale outran our wisdom about what to do with the results, and closing that gap, better counseling, real pathways to act, and honesty about what we cannot yet change, matters more than the next drop in sequencing cost.
“Knowledge is what to do. Wisdom, and this is the important part, is what not to do.” Dr. Junaid Kalia
Connect with us
Dr. Junaid Kalia, Neurocritical Care Specialist, Founder of Savelife.AI™
DR GPT™ Harvey Castro, ER Physician, #DrGPT
Edward Marx, CEO, Advisor
Originally published on my Substack. Planning a session on precision medicine or healthspan? Explore my healthcare AI keynotes.